Literature DB >> 16639773

Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16639773     DOI： 10.1002/sim.2584

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


× No keyword cloud information.
  52 in total

Review 1.  Reporting of Design Features and Analysis Details in Randomized Clinical Trials of Procedural Treatments for Cancer Pain: An ACTTION Systematic Review.

Authors:  Daniel Rothstein; Rachel A Kitt; Shannon M Smith; Salahadin Abdi; Mitchell P Engle; Michael P McDermott; Srinivasa N Raja; Dennis C Turk; Robert H Dworkin; Jennifer S Gewandter
Journal:  Reg Anesth Pain Med       Date:  2017 May/Jun       Impact factor: 6.288

Review 2.  Clinical risk management of herb-drug interactions.

Authors:  Peter A G M De Smet
Journal:  Br J Clin Pharmacol       Date:  2006-11-20       Impact factor: 4.335

3.  European regulatory perspectives for innovative therapies.

Authors:  S Ormarsdottir; J Y Reginster; E Abadie
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

Review 4.  Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Eric Abadie; David Barnett; Franz König; Steven Pearson
Journal:  Nat Rev Drug Discov       Date:  2010-02-26       Impact factor: 84.694

Review 5.  Sources, impacts and trends of pharmaceuticals in the marine and coastal environment.

Authors:  Sally Gaw; Kevin V Thomas; Thomas H Hutchinson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-11-19       Impact factor: 6.237

Review 6.  Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective.

Authors:  Marc Maliepaard; Charity Nofziger; Marisa Papaluca; Issam Zineh; Yoshiaki Uyama; Krishna Prasad; Christian Grimstein; Michael Pacanowski; Falk Ehmann; Silvia Dossena; Markus Paulmichl
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

7.  ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies.

Authors:  Rashmi R Shah; Joel Morganroth
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

8.  Design of non-inferiority randomized trials using the difference in restricted mean survival times.

Authors:  Isabelle R Weir; Ludovic Trinquart
Journal:  Clin Trials       Date:  2018-08-03       Impact factor: 2.486

Review 9.  Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.

Authors:  Grace Wangge; Olaf H Klungel; Kit C B Roes; Anthonius de Boer; Arno W Hoes; Mirjam J Knol
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

10.  Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.

Authors:  Marc Trellu; Jean-Baptiste Fau; Pierre Cortez; Sue Cheng; Isabelle Paty; Emmanuelle Boëlle; François Donat; Ger-Jan Sanderink
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.